<DOC>
	<DOCNO>NCT00544154</DOCNO>
	<brief_summary>The main purpose study determine efficacy CDP870 treat RA signs/symptoms patient partial responder MTX . Other purpose show additional efficacy without increase toxicity immunogenic response CDP870 combine CDP870 MTX therapy .</brief_summary>
	<brief_title>Efficacy Safety CDP870 Methotrexate Compared Methotrexate Alone Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>male/female , 1875 year old , inclusive diagnosis adultonset RA active disease receive methotrexate stable dose folic acid contraindication methotrexate antiTNF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>CDP870</keyword>
	<keyword>Certolizumab pegol</keyword>
</DOC>